Special Reports

ai-report-cover-wpl-jpg.JPG

WIPR Patents Live: The AI Report

Artificial intelligence (AI) and its relationship to IP has long been a hot topic. Over the past few months, World IP Review has been delving into some of the most-debated AI discussions, and have compiled them into this special report.

  • Expert insight into how IP offices are harnessing AI to better protect IP
  • In-depth analysis on which organisations are leading AI innovation
  • A detailed exploration of China’s position in AI patenting
  • Exclusive comment on the future of AI inventorship
 
 
appdetex-whitepaper-jpg.JPG

Infringing Apps and Your Brand: A Guide to Developing Your Enforcement Strategy

The goal of this guide is to discuss how to design an app enforcement strategy that addresses the risks posed to your business by infringing mobile apps.

Topics include:

  • How your mobile commerce goals impact your enforcement strategy
  • How to carry out enforcement at scale
  • How to build an efficient enforcement framework
 
 
abe.jpg

Case Study: The Broad Institute’s CRISPR-Cas9 Patents

CRISPR patents have been a hot topic around the world for a few years now, with much of the focus on Europe and the US. The picture in Japan is less well known but equally interesting. We're delighted to share with you a case study on ‘The Broad Institute’s CRISPR-Cas9 Patents’ in partnership with Abe & Partners.

Access the case study for an in-depth exploration of the dispute between the Broad Institute and the Japanese Patent Office (JPO) around genome editing technology.

 
 
navigating-smu.jpg

Navigating the second medical use landscape

In recent years, second medical use patents have been the subject of myriad litigations and a selection of interesting decisions across many jurisdictions has resulted. Our sister brand LSIPR recently tackled this tricky and timely topic.

This report addresses: 

  • In-depth analysis of the significance of second medical use patents on pharmaceutical R&D
  • Expert opinion on the consequences and complications from Warner-Lambert v Actavis
  • Exclusive insight into the regulatory environment for second medical use patents and how this regulation can be used to assist in their protection
  • Strategies that pharmaceutical companies can adopt to mitigate cross-label use without resorting to patent enforcement.

WIPR